Common cholesterol-lowering drug may strongly reduce COVID-19 infection

Credit: CC0 Public Domain

In a recent study from the Hebrew University of Jerusalem, researchers found that a simple drug that has been used to lower cholesterol levels could be used to treat COVID-19.

The drug is called Fenofibrate (Tricor).

Over the last three months, the researchers had focused on the ways in which the SARS-CoV-2 changes patients’ lungs in order to reproduce itself.

They found this virus prevents the routine burning of carbohydrates. As a result, large amounts of fat accumulate inside lung cells, a condition the virus needs in order to reproduce.

This new finding of SARS CoV-2 may help explain why patients with high blood sugar and cholesterol levels are often at a particularly high risk to develop COVID-19.

The study is published in Cell Press Sneak Peak. One author is Professor Yaakov Nahmias.

Viruses are parasites that lack the ability to replicate on their own, so they take control of our cells to help accomplish that task.

The researchers say by understanding how the SARS-CoV-2 controls the metabolism, they can wrestle back control from the virus and deprive it of the very resources it needs to survive.

With this information in hand, the team began to screen FDA-approved medications that interfere with the virus’ ability to reproduce.

In lab studies, the cholesterol-lowering drug Fenofibrate (Tricor) showed extremely promising results.

By allowing lung cells to burn more fat, fenofibrate breaks the virus’ grip on these cells and prevents SARS CoV-2’s ability to reproduce.

In fact, within only five days of treatment, the virus almost completely disappeared.

While there are many international efforts currently underway to develop a coronavirus vaccine, studies suggest that vaccines may only protect patients for a few months.

Therefore, blocking the virus’ ability to function, rather than neutralizing its ability to strike in the first place, may be the key to turning the tables on COVID-19.

If these findings are borne out by clinical studies, this treatment could potentially downgrade COVID-19’s severity into nothing worse than a common cold.

Copyright © 2020 Knowridge Science Report. All rights reserved.